4:53 PM
 | 
Jan 03, 2014
 |  BC Extra  |  Top Story

AZ acquires Probiodrug's CDK9 inhibitor program

AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired a cyclin dependent kinase 9 (CDK9) inhibitor program from

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >